| |
β-Amyloid (1-42), human  |
|
|
| Cat. No. |
Size |
Price |
Figures |
|---|
RP10017-0.5 mg
| 0.5 mg | $ 119.00 | HPLC: 20060721145613 (PDF)
MS: 20060721145553 (PDF)
MSDS: 20080923043843 (PDF)
COA: RP10017_78425001022710XB (PDF)
COA: RP10017_78425001091009XB (PDF)
PROTOCOL: 20100407015038 (PDF)
COA: RP10017_86847001020310WY (PDF)
EXAMPLE:
Zoom
References:
- Murphy GM Jr, et al. Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders. Am J Pathol. May 1994; 144(5): 1082-1088.
- Ambroggio EE, et al. Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1-42: a membrane-disrupting peptide. Biophys J. Apr 2005; 88(4): 2706-2713.
- Hulstaert F, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology. May 1999; 52(8): 1555-1562.
|
|---|
RP10017-1 mg
| 1 mg | $ 214.00 |
|---|
| Full Name | |
Sequence
(one-letter code) |
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA | Sequence
(three-letter code) | {ASP}{ALA}{GLU}{PHE}{ARG}{HIS}{ASP}{SER}{GLY}{TYR}
{GLU}{VAL}{HIS}{HIS}{GLN}{LYS}{LEU}{VAL}{PHE}{PHE}
{ALA}{GLU}{ASP}{VAL}{GLY}{SER}
{ASN}{LYS}{GLY}{ALA}{ILE}
{ILE}{GLY}{LEU}{MET}{VAL}{GLY}{GLY}{VAL}{VAL}{ILE}
{ALA} |
|---|
| Description | This peptide is well suited to the quantitative determination of A 42 peptide. Alzheimer’s disease (AD) is characterized by the presence of extracellular plaques and intracellular neurofibrillary tangles (NFTs) in the brain. The major protein component of these plaques is beta amyloid peptide (A), a 40- to 43- amino-acid peptide cleaved from amyloid precursor protein by secretase (BACE) and a putative (gamma) secretase. Increased release of the ‘longer forms’ of A peptide, A 42 and A 43, which have a greater tendency to aggregate than A 40, occurs in individuals expressing certain genetic mutations, expressing certain ApoE alleles or may other, still undiscovered factors. |
|---|
| Solubility | Insoluble in water, may be dissolved in any buffer with pH greater than 9 |
|---|
| Formula | C203H311N55O60S1 |
|---|
| M.W. | 4514.1 |
|---|
| Cas | 107761-42-2 |
|---|
| Purity | > 95% |
|---|
| Storage | Store at -20°C | | Notes | This product is a chemically-modified β-amyloid (1-42) precursor, which belongs to GenScript’s "click peptides".
The "click peptides" are best described by the following key features:
1. Enhanced Stability—The O-acyl moiety within the click peptide is stable even under acidic pH.
2. Convenient and quick process—The "click peptides" can be easily converted to native peptide at pH 7.4 or above.
3. No by-product formation in the conversion process
4. High Solubility—15 mg/ml for click peptide in water compared to 0.14 mg/ml for the native peptide.
5. Superior quality—After the "click", the aggregative property of the peptides is significantly minimized compared to its native format. |
|---|
| * For Non-Clinical Research Use Only *
 |
1 |
Peptide Services: GenScript's peptide synthesis services include standard chemical peptide synthesis, peptide modification, peptide libraries, and recombinant peptide expression.
|
2 |
Standard Peptide Synthesis: GenScript offers quality peptides at the most competitive prices in the industry, starting at $2.56 per amino acid. GenScript FlexPeptideTM technology can synthesize peptide as long as 200 amino acids, a world record for such technology.
|
3 |
Peptide Modifications: GenScript offers a wide range of peptide modification services including isotope labeling (2H, 15N, and 13C), multiple disulfide bonds, multiple phosphorylations, KLH, BSA, ovalbumin, amidation, acetylation, biotin, FITC, etc.
|
4 |
Peptide Libraries: GenScript has developed a rapid high-throughput parallel peptide synthesis platform, providing custom libraries of unbound peptides of 5-20 mer at very competitive prices.
|
Our customer service is available 24 hours a day, Monday through Friday. You may contact us any time for assistance.
|
|
